author-photo

Vanita R. Aroda

Brigham and Women's Hospital
MedStar Health
Memorial Hospital of South Bend

205

Papers

4506

Citations

Citation Trend

Filter By

Papers (205) Sort By

Journal Conference Others

Abstract 10159: Underuse of Evidence-based Therapies for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease: Insights from Clinical Research Networks in the United States

2021 Circulation
Show All
- Source
- Cite
- Save
Citations (0)
Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data.

2021 Pharmacoepidemiology and Drug Safety
Show All
- Source
- Cite
- Save
Citations (2)
661-P: Reduced Glycemic Variability with Once-Weekly Semaglutide vs. Active Comparators in Post-hoc Analysis of the SUSTAIN Program

2021 Diabetes
Show All
- Source
- Cite
- Save
Citations (0)
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.

2021 Diabetes Care
Show All
- Source
- Cite
- Save
Citations (2)
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.

2021 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Long-term effects of lifestyle and metformin interventions in DPP on bone density.

2021 Osteoporosis International
Show All
- Source
- Cite
- Save
Citations (0)
Switching to iGlarLixi vs Continuation of Daily or Weekly GLP-1 RA in Insufficiently Controlled Type 2 Diabetes: A LixiLan-G Trial Subgroup Analysis by HbA1c and GLP-1 RA Use at Screening.

2021 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Author response for "Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study"

2021 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (0)
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes

2021 Current Diabetes Reports
Show All
- Source
- Cite
- Save
Citations (1)
606-P: Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D

2021 Diabetes
Show All
- Source
- Cite
- Save
Citations (0)